Physician
Oncology
Dr. Hyam I. Levitsky, MD
|
|
Give Review
Hyam Levitsky works in the field of Oncology. He attended Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a one of the best medicals schools. Johns Hopkins University School of Medicine has a rank of 3 in research and a 29 in primary care He over the years received 1 awards: "Elected Member". Dr. Hyam I. Levitsky is also a published doctor. He has 80 publication published. The most recent publication is: The central role of CD4(+) T cells in the antitumor immune response.
Publications
- Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.
- Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.
- TE-array-a high throughput tool to study transposon transcription.
- Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.
- Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.
- Molecular engineering of the antitumor immune response.
- Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines.
- Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses.
- Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.
- The central role of CD4(+) T cells in the antitumor immune response.
- Prostate cancer vaccines: current status.
- The antitumor immune response as a problem of self-nonself discrimination: implications for immunotherapy.
- Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting ant...
- Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice.
- High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas.
- Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).
- Magnetoelectroporation: improved labeling of neural stem cells and leukocytes for cellular magnetic resonance imaging using a single FDA-approved agent.
- Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments.
- In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.
- Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.
- Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.
- Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.
- Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.
- Tumor-specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines.
- High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.
- K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
- "MIATA"-minimal information about T cell assays.
- Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremis...
- Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.
- Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes.
- Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer.
- The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells.
- Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.
- Role of LAG-3 in regulatory T cells.
- Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to...
- Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.
- Evaluation of current cancer immunotherapy: hemato-oncology.
- Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.
- Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance.
- Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.
- Characterization of chronic myeloid leukemia stem cells.
- Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.
- In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.
- Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymph...
- Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy.
- When magic bullets miss their mark.
- Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignan...
- Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T-cell tolerance.
- Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines.
- CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes.
- Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete gra...
- In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.
- A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines.
- Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.
- Chronic oxytocin pretreatment inhibits adenylyl cyclase activity in cultured rat myometrial cells.
- Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.
- Tolerance and cancer: a critical issue in tumor immunology.
- Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines.
- Accessories for naked DNA vaccines.
- Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.
- Canarypox virus vectors for gene transfer in cancer immunotherapy.
- The best cytokine for the job.
- Tumors derived from antigen presenting cells.
- Enhanced immune priming with spatial distribution of paracrine cytokine vaccines.
- Arterial delivery of genetically labelled skeletal myoblasts to the murine heart: long-term survival and phenotypic modification of implanted myoblasts.
- Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
- Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates p...
- In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter.
- Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.
- Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials.
- Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.
- Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.
- Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell ...
- A reassessment of the role of B7-1 expression in tumor rejection.
- Cell polarity: an examination of its behavioral expression and its consequences for polymorphonuclear leukocyte chemotaxis.
- Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.
- Early invasive CNS aspergillosis. An easily missed diagnosis.
- Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.
- The fate of CD4-8- T cell receptor-alpha beta+ thymocytes.
Schools
Johns Hopkins University School of Medicine
Johns Hopkins Hospital
Johns Hopkins Onco Center
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Elected Member
Education
-
Johns Hopkins University -
Johns Hopkins University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. Jean A. Yared, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley D. Walker, MD |
|
|
Dr. John M. Wrangle, MD |
|
|
Dr. Arif Hussain, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward A. Sausville, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Samuel R. Denmeade, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Lei Zheng, MD
This Doctor is OpenDoctor Recommended.
|